Literature DB >> 2161417

A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus.

M N Prichard1, S R Turk, L A Coleman, S L Engelhardt, C Shipman, J C Drach.   

Abstract

Although the virus yield reduction assay is a powerful technique for evaluating the efficacy of antiviral compounds, it is not routinely utilized due to its labor-intensive nature. This procedure was modified, developed, thereby reducing greatly the time and effort required to perform yield reduction assays. Monolayer cultures of mammalian cells were grown in 96-well microtiter tissue culture plates and infected with virus. Test compounds were added and serially diluted directly with the plates. Following a cycle of virus replication, culture lysates were made and serially diluted in a separate set of uninfected cultures grown in microtiter plates. The cultures were incubated, plaques were enumerated in wells containing 5 to 20 plaques, and virus titers were calculated. To illustrate the use of the assay the known antiviral drugs acyclovir and ganciclovir were evaluated using this procedure. Ninety percent inhibitory concentrations for the respective drugs were 3 microM and 0.7 microM against herpes simplex virus type 1 and 60 microM and 1 microM against human cytomegalovirus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161417     DOI: 10.1016/0166-0934(90)90091-s

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  30 in total

1.  Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus.

Authors:  Paula M Krosky; Katherine Z Borysko; M Reza Nassiri; Rodrigo V Devivar; Roger G Ptak; Michelle G Davis; Karen K Biron; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies.

Authors:  Valeria M Zakharova; Michaela Serpi; Ivan S Krylov; Larryn W Peterson; Julie M Breitenbach; Katherine Z Borysko; John C Drach; Mindy Collins; John M Hilfinger; Boris A Kashemirov; Charles E McKenna
Journal:  J Med Chem       Date:  2011-08-03       Impact factor: 7.446

Review 3.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

4.  Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.

Authors:  James M Markert; James J Cody; Jacqueline N Parker; Jennifer M Coleman; Kathleen H Price; Earl R Kern; Debra C Quenelle; Alfred D Lakeman; Trenton R Schoeb; Cheryl A Palmer; Samuel C Cartner; G Yancey Gillespie; Richard J Whitley
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 5.  Current and potential treatments for ubiquitous but neglected herpesvirus infections.

Authors:  Jonathan E Gable; Timothy M Acker; Charles S Craik
Journal:  Chem Rev       Date:  2014-10-02       Impact factor: 60.622

6.  Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo[2,3-d]pyrimidines does not correlate with antiviral activity.

Authors:  David L Evers; Julie M Breitenbach; Katherine Z Borysko; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.

Authors:  David L Evers; Gloria Komazin; Roger G Ptak; Dongjin Shin; Brian T Emmer; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27.

Authors:  Gloria Komazin; Roger G Ptak; Brian T Emmer; Leroy B Townsend; John C Drach
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Inhibition of human cytomegalovirus in culture by alkenyl guanine analogs of the thiazolo[4,5-d]pyrimidine ring system.

Authors:  A F Lewis; J C Drach; S M Fennewald; J H Huffman; R G Ptak; J P Sommadossi; G R Revankar; R F Rando
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Human cytomegalovirus uracil DNA glycosylase is required for the normal temporal regulation of both DNA synthesis and viral replication.

Authors:  M N Prichard; G M Duke; E S Mocarski
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.